Medical Science and Medical Industry. The Formation of the American Pharmaceutical Industry. Jonathan Liebenau. Johns Hopkins University Press, Baltimore, MD, 1987. x, 207 pp. $35. Henry E. Sigerist Series in the History of Medicine

Science ◽  
1988 ◽  
Vol 239 (4841) ◽  
pp. 801-802
Author(s):  
J. W. Servos
Health ◽  
2019 ◽  
pp. 1-6
Author(s):  
Peter Adamson

This introduction to the volume gives an overview of the chapters, setting out a case for integrating the history of philosophy with the history of medicine and sketching some of the key philosophical issues that arise around the concept of health. These include the difficulty of defining “health,” the mind-body relationship, and questions about how philosophy informs medical science and practice. A central idea is that the concept of health operates at two levels, the mental and the physical (or the soul and the body), so that ethical virtue and physical well-being have often been seen as parallel or mutually dependent.


2020 ◽  
Vol 58 (4) ◽  
pp. 533-558
Author(s):  
Joseph M. Gabriel ◽  
Bennett Holman

This paper describes one possible origin point for fraudulent behavior within the American pharmaceutical industry. We argue that during the late nineteenth century therapeutic reformers sought to promote both laboratory science and increasingly systematized forms of clinical experiment as a new basis for therapeutic knowledge. This process was intertwined with a transformation in the ethical framework in which medical science took place, one in which monopoly status was replaced by clinical utility as the primary arbiter of pharmaceutical legitimacy. This new framework fundamentally altered the set of epistemic virtues—a phrase we draw from the philosophical field of virtue epistemology—considered necessary to conduct reliable scientific inquiry regarding drugs. In doing so, it also made possible new forms of fraud in which newly emergent epistemic virtues were violated. To make this argument, we focus on the efforts of Francis E. Stewart and George S. Davis of Parke, Davis & Company. Therapeutic reformers within the pharmaceutical industry, such as Stewart and Davis, were an important part of the broader normative and epistemic transformation we describe in that they sought to promote laboratory science and systematized clinical trials toward the twin goals of improving pharmaceutical science and promoting their own commercial interests. Yet, as we suggest, Parke, Davis & Company also serves as an example of a company that violated the very norms that Stewart and Davis helped introduce. We thus seek to describe one possible origin point for the widespread fraudulent practices that now characterize the pharmaceutical industry. We also seek to describe an origin point for why we conceptualize such practices as fraudulent in the first place.


Sign in / Sign up

Export Citation Format

Share Document